Prospecting Novel Microbiomes for Antibiotic Compounds Using Metagenomics and Genome Mining

Total Page:16

File Type:pdf, Size:1020Kb

Prospecting Novel Microbiomes for Antibiotic Compounds Using Metagenomics and Genome Mining UCL SCHOOL OF PHARMACY BRUNSWICK SQUARE Prospecting Novel Microbiomes for Antibiotic Compounds using Metagenomics and Genome Mining Tim Ali Charles Walker Thesis submitted in fulfilment of the requirements of the UCL degree of Doctor of Philosophy 2020 I, Tim Walker, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. Signed: --------------------- 2 Abstract There has been a void in the discovery and development of new antibiotic classes over the past four decades due, in part, to the traditional bioprospecting pipeline becoming inefficient from high compound rediscovery rates and high costs. The need for new antibiotic classes is urgent as antimicrobial drug resistant infections are now a major public health concern. Strategies such as exploring novel environments, use of next-generation sequencing, and metagenomics may reduce rediscovery rates and costs which could help accelerate lead discovery and encourage greater participation in bioprospecting. Whole genome-sequencing and analysis was used to characterise four bacterial strains (Y1-4) isolated from raw honey that were shown to have antibiotic activity. The isolates were identified as Bacillus and were closely related but distinctive strains with variations amongst their secondary metabolite profiles. All isolates contained a gene cluster homologous to AS- 48, a circular bacteriocin produced by Enterococcus faecalis, which has broad-spectrum antibiotic activity. To date, no example of this bacteriocin has been reported in Bacillus. This work demonstrated the value of whole-microbial genome sequencing for dereplication. A pipeline for the low-cost sequencing and assembly of bacterial genomes using Oxford Nanopore MinION was developed in order to produce contiguous and accurate genome assemblies for taxonomic and bioprospecting analysis. The pipeline developed used a combination of Nanopore draft assembly by Canu and polishing with RACON and Nanopolish, with final polishing with Illumina reads using Pilon. The Nanopore-only assembly of Streptomyces coelicolor A3(2) produced was contiguous and covered 98.9 % of reference. AntiSMASH analysis identified the full secondary metabolite profile of the genome through homology searches. However, indel rates were high (66.82 per 100 kbp) causing fragmented gene annotations which limited secondary metabolite structure prediction. Illumina read polishing reduced indels (2.03 per 100 kbp) and enabled accurate structure prediction from the identified biosynthetic pathways. This demonstrates that Nanopore sequencing can provide a viable dereplication strategy by detection of known biosynthetic pathways. Additionally, supplementation with Illumina sequencing can allow for structure prediction of biosynthetic pathways which could inform chemical extraction strategies for novel pathways. Nanopore sequencing was further utilised to characterise an antibiotic producing isolate (KB16) active against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus from the hot spring of the Roman Baths, UK. Genomic analysis showed KB16 3 to be highly related to Streptomyces canus and to contain 26 putative secondary metabolite gene clusters - some of which were potentially novel. One of the gene clusters was identified as encoding the antibiotic albaflavenone. Attempts to chemically identify the antibiotic produced by KB16 showed that it may produce multiple antimicrobial compounds. These findings demonstrate the value in prospecting underexplored environments such as the Roman Baths for microbially-derived antimicrobial leads. A PCR screen was used to amplify NRPS and PKS gene fragments from a human oral metagenome. Analysis of the fragments suggested that some are from uncharacterised gene clusters. Nanopore shotgun metagenomic sequencing was used to profile the water of the Roman Baths which revealed a diverse microbiome of species with reported metabolic characteristics that are in keeping with the known geochemistry of the waters and aligned with 16S rRNA analysis. Further analysis also identified putative heavy metal resistance genes which can be a co-marker for their metabolism and aligned with the chemical properties of the water. These findings demonstrate the potential value in these sites for bioprospecting whilst also giving insight that can inform bioprospecting strategies. The investigations also highlight the utility of Nanopore sequencing for taxonomic and functional gene profiling of environmental microbiomes. In combination these findings have all contributed information on novel environments, potential isolate leads, and cost-efficient methodologies to accelerate the discovery of microbially-derived antibiotics. 4 Impact Statement Discovery of new antibiotic classes has stalled over the past four decades. This has been caused in part by the ‘traditional’ model of bioprospecting becoming less economical from high rediscovery rates and resource costs. During this time, antimicrobial resistant infections have continued to proliferate and are a major global public health concern. Leading to warnings from public health authorities of the risk of a ‘post-antibiotic age’ where current antibiotics have lost all effectiveness. The potential costs of such a situation to the global economy, public health, and quality of life are estimated to be high. Therefore, the need for the development of new antibiotic classes with novel modes of action is urgent. To fill the discovery void more novel antibiotic lead compounds need to be discovered. By utilising new technologies and approaches that may mitigate the issues that led to the decline in bioprospecting then more research groups and industry may begin searching again. The work in this thesis has detailed attempts to discover novel bacterial isolates producing antibiotic compounds and develop strategies to improve the bioprospecting pathway using Oxford Nanopore long-read sequencing and genome-mining for dereplication. To this end, five bacterial isolates (four from honey and one from the hot springs of the Roman Baths) with antibiotic activity were characterised. The analysis identified aspects of the isolates phylogenetics and secondary metabolism profiles. Which revealed that the isolates may have biosynthetic gene clusters for potentially novel compounds. The impact of this is that it forms the basis for further isolation of these compounds. A pipeline for the whole-genome sequencing and annotation of isolates using Oxford Nanopore technology was developed and validated in the analysis of a novel isolate from the Roman Baths, UK. This pipeline can allow researchers to produce accurate genome assembles to dereplicate and prioritise lead isolates quickly and efficiently, and thus make bioprospecting an economical and viable strategy for more researchers to perform. The results of the analysis revealed the discovery of known antibiotic compounds and highlighted how taxonomy alone is not a marker of expected secondary metabolite potential. Genome-mining also revealed the presence of gene pathways for AS-48 bacteriocin in the Bacillus isolates from honey. This is the first report of this compound in this genus and further highlights the disconnect between taxonomy and biosynthetic potential. This is an important finding for bioprospectors to ensure that their dereplication strategies do not discount lead isolates wrongly. 5 In addition, the microbiome of the Roman Baths, UK was profiled using Oxford Nanopore sequencing. This is a UNESCO world heritage site of significant cultural and geological importance, and this was the first survey of its kind to be performed on this site. The findings revealed microbial taxa not previously reported to be present in the waters and gives a basis by which researchers can plan studies into the site from both a bioprospecting and ecological point of view. The Oxford Nanopore sequencing pipeline used to profile the microbiome also revealed evidence for the presence of metal resistance genes, which demonstrates the potential of the pipeline for functional gene profiling of the site. 6 Table of Contents Title Page 1 Declaration of Authenticity 2 Abstract 3 Impact Statement 5 Table of Contents 7 List of Figures 12 List of Tables 15 Abbreviations 17 Chapter 1. Introduction 20 1.1. Antibiotics and their Modes of Action and Resistance Mechanisms 21 1.1.1. Inhibition of Cell Wall Synthesis 21 1.1.2. Membrane Disruption 22 1.1.3. Inhibition of Nucleic Acid Synthesis 22 1.1.4. Inhibition of Protein Synthesis 23 1.1.5. Inhibition of Folic Acid Synthesis 23 1.1.6. Biochemical Mechanisms of Antibiotic Resistance 23 1.1.6.1. Reduction in Intracellular Concentrations 24 1.1.6.2. Modification of Antibiotic Target 25 1.1.6.3. Inactivation of Antibiotic 25 1.2 Microbially-Derived Antibiotics 26 1.3. Principles of Bioactivity-Guided Isolation 32 1.4. Biosynthetic Classes of Major Microbially-derived Antibiotics 35 1.4.1. Polyketide Synthases and Non-Ribosomal Synthases 35 1.4.2. Ribosomally Synthesized and Post-Translationally Modified Peptides 37 1.4.2.1. Lantipeptides 39 1.4.2.2. Thiopeptides 40 1.4.2.3. Lasso Peptides 41 1.4.2.4. Bottromycins 42 1.4.2.5. Cyanobactins 42 1.4.2.6. Glycocins 42 1.4.2.7. Bacterial Head-to-Tail Cyclised Peptides 43 1.4.2.8. Linear azole(in)e-containing peptides (LAPs) 44 1.4.2.9. Proteusins 44 1.4.3. Terpenes 44 1.5. The Decline in Antibiotic Discovery and the Need for New Antibiotics 47 1.6. New Approaches
Recommended publications
  • Current Topics in Medicinal Chemistry, 2020, 20, 1291-1299 REVIEW ARTICLE
    Send Orders for Reprints to [email protected] 1291 Current Topics in Medicinal Chemistry, 2020, 20, 1291-1299 REVIEW ARTICLE ISSN: 1568-0266 eISSN: 1873-4294 Impact Factor: The Microbiome: A Reservoir to Discover New Antimicrobials Agents 3.442 The international journal for in-depth reviews on Current Topics in Medicinal Chemistry BENTHAM SCIENCE Sébastien Boutin1,2,* and Alexander H. Dalpke3 1Department of Infectious Diseases, Medical Microbiology and Hygiene, University Hospital Heidelberg, 69120 Hei- delberg, Germany; ²German Center for Lung Research (DZL), TLRC Heidelberg, 69120 Heidelberg, Germany; 3Institute of Medical Microbiology and Hygiene, Medical Faculty, Technische Universität Dresden, 01307 Dresden, Gemany Abstract: Nature offered mankind the first golden era of discovery of novel antimicrobials based on A R T I C L E H I S T O R Y the ability of eukaryotes or micro-organisms to produce such compounds. The microbial world proved to be a huge reservoir of such antimicrobial compounds which play important functional roles in every Received: November 11, 2019 environment. However, most of those organisms are still uncultivable in a classical way, and therefore, Revised: February 10, 2020 the use of extended culture or DNA based methods (metagenomics) to discover novel compounds Accepted: February 17, 2020 promises usefulness. In the past decades, the advances in next-generation sequencing and bioinformat- DOI: 10.2174/1568026620666200320112731 ics revealed the enormous diversity of the microbial worlds and the functional repertoire available for studies. Thus, data-mining becomes of particular interest in the context of the increased need for new antibiotics due to antimicrobial resistance and the rush in antimicrobial discovery.
    [Show full text]
  • Infant Antibiotic Exposure Search EMBASE 1. Exp Antibiotic Agent/ 2
    Infant Antibiotic Exposure Search EMBASE 1. exp antibiotic agent/ 2. (Acedapsone or Alamethicin or Amdinocillin or Amdinocillin Pivoxil or Amikacin or Aminosalicylic Acid or Amoxicillin or Amoxicillin-Potassium Clavulanate Combination or Amphotericin B or Ampicillin or Anisomycin or Antimycin A or Arsphenamine or Aurodox or Azithromycin or Azlocillin or Aztreonam or Bacitracin or Bacteriocins or Bambermycins or beta-Lactams or Bongkrekic Acid or Brefeldin A or Butirosin Sulfate or Calcimycin or Candicidin or Capreomycin or Carbenicillin or Carfecillin or Cefaclor or Cefadroxil or Cefamandole or Cefatrizine or Cefazolin or Cefixime or Cefmenoxime or Cefmetazole or Cefonicid or Cefoperazone or Cefotaxime or Cefotetan or Cefotiam or Cefoxitin or Cefsulodin or Ceftazidime or Ceftizoxime or Ceftriaxone or Cefuroxime or Cephacetrile or Cephalexin or Cephaloglycin or Cephaloridine or Cephalosporins or Cephalothin or Cephamycins or Cephapirin or Cephradine or Chloramphenicol or Chlortetracycline or Ciprofloxacin or Citrinin or Clarithromycin or Clavulanic Acid or Clavulanic Acids or clindamycin or Clofazimine or Cloxacillin or Colistin or Cyclacillin or Cycloserine or Dactinomycin or Dapsone or Daptomycin or Demeclocycline or Diarylquinolines or Dibekacin or Dicloxacillin or Dihydrostreptomycin Sulfate or Diketopiperazines or Distamycins or Doxycycline or Echinomycin or Edeine or Enoxacin or Enviomycin or Erythromycin or Erythromycin Estolate or Erythromycin Ethylsuccinate or Ethambutol or Ethionamide or Filipin or Floxacillin or Fluoroquinolones
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • Conjunctivitis Or Worse?
    Red Eye in Dogs and CatS: Conjunctivitis or Worse? Tracy Revoir, DVM Senior Manager of Veterinary Support, Dechra Veterinary Products It should come as no surprise that conjunctivitis is Common Causes of Conjunctivitis the most common ophthalmic disorder in dogs and cats. But because the clinical signs of conjunctivitis If you do confirm conjunctivitis, the next step is can mimic those of more serious ophthalmic identifying the cause. If both eyes are affected and diseases (glaucoma and uveitis), it’s important to abnormal clinical signs are apparent in other body confirm your diagnosis. systems, think underlying systemic disease. If only one eye is affected, rule out infection, tear film What are important clues to the severity of the deficiencies, an irritant, anatomical abnormality, condition? With conjunctivitis, the inflammation or deeper ocular disease. should be limited to the conjunctiva. Hyperemic conjunctival vessels are superficial, branching, In dogs, conjunctivitis can result from anatomical and bright red. They are movable over the deeper disorders, irritants, infection (usually bacterial), or episcleral vessels and can be blanched with topical atopy. Most bacterial infections are secondary dilute phenylephrine. With glaucoma and uveitis, the conditions, most often to allergies. In cats, herpes- episcleral vessels are engorged; they are dark red, virus and Chlamydophila felis are the most common deep, straight, and immobile and do not blanch with causes of conjunctivitis. Atopy can also be topical dilute phenylephrine. With conjunctivitis, an issue in cats. the Schirmer tear test and intraocular pressures are normal. And the cornea should be clear and no aqueous flare should be present. The pupil and Addressing the Problem pupillary responses are normal and intraocular structures should be visible.
    [Show full text]
  • Topical Antibiotics for Impetigo: a Review of the Clinical Effectiveness and Guidelines
    CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Topical Antibiotics for Impetigo: A Review of the Clinical Effectiveness and Guidelines Service Line: Rapid Response Service Version: 1.0 Publication Date: February 21, 2017 Report Length: 23 Pages Authors: Rob Edge, Charlene Argáez Cite As: Topical antibiotics for impetigo: a review of the clinical effectiveness and guidelines. Ottawa: CADTH; 2017 Feb. (CADTH rapid response report: summary with critical appraisal). ISSN: 1922-8147 (online) Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document.
    [Show full text]
  • Farrukh Javaid Malik
    I Farrukh Javaid Malik THESIS PRESENTED TO OBTAIN THE GRADE OF DOCTOR OF THE UNIVERSITY OF BORDEAUX Doctoral School, SP2: Society, Politic, Public Health Specialization Pharmacoepidemiology and Pharmacovigilance By Farrukh Javaid Malik “Analysis of the medicines panorama in Pakistan – The case of antimicrobials: market offer width and consumption.” Under the direction of Prof. Dr. Albert FIGUERAS Defense Date: 28th November 2019 Members of Jury M. Francesco SALVO, Maître de conférences des universités – praticien hospitalier, President Université de Bordeaux M. Albert FIGUERAS, Professeur des universités – praticien hospitalier, Director Université Autonome de Barcelone Mme Antonia AGUSTI, Professeure, Vall dʹHebron University Hospital Referee Mme Montserrat BOSCH, Praticienne hospitalière, Vall dʹHebron University Hospital Referee II Abstract A country’s medicines market is an indicator of its healthcare system, the epidemiological profile, and the prevalent practices therein. It is not only the first logical step to study the characteristics of medicines authorized for marketing, but also a requisite to set up a pharmacovigilance system, thus promoting rational drug utilization. The three medicines market studies presented in the present document were conducted in Pakistan with the aim of describing the characteristics of the pharmaceutical products available in the country as well as their consumption at a national level, with a special focus on antimicrobials. The most important cause of antimicrobial resistance is the inappropriate consumption of antimicrobials. The results of the researches conducted in Pakistan showed some market deficiencies which could be addressed as part of the national antimicrobial stewardship programmes. III Résumé Le marché du médicament d’un pays est un indicateur de son système de santé, de son profil épidémiologique et des pratiques [de prescription] qui y règnent.
    [Show full text]
  • Neomycin and Polymyxin B Sulfates and Bacitracin Zinc Ophthalmic Ointment, USP)
    NDA 50-417/S-011 Page 3 NEOSPORIN® Ophthalmic Ointment Sterile (neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment, USP) Description: NEOSPORIN Ophthalmic Ointment (neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment) is a sterile antimicrobial ointment for ophthalmic use. Each gram contains: neomycin sulfate equivalent to 3.5 mg neomycin base, polymyxin B sulfate equivalent to 10,000 polymyxin B units, bacitracin zinc equivalent to 400 bacitracin units, and white petrolatum, q.s. Neomycin sulfate is the sulfate salt of neomycin B and C, which are produced by the growth of Streptomyces fradiae Waksman (Fam. Streptomycetaceae). It has a potency equivalent of not less than 600 µg of neomycin standard per mg, calculated on an anhydrous basis. The structural formulae are: [Structure] Polymyxin B sulfate is the sulfate salt of polymyxin B 1 and B 2 , which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formulae are: [Structure] Bacitracin zinc is the zinc salt of bacitracin, a mixture of related cyclic polypeptides (mainly bacitracin A) produced by the growth of an organism of the licheniformis group of Bacillus subtilis var Tracy. It has a potency of not less than 40 bacitracin units per mg. The structural formula is: [Structure] CLINICAL PHARMACOLOGY: A wide range of antibacterial action is provided by the overlapping spectra of neomycin, polymyxin B sulfate, and bacitracin. Neomycin is bactericidal for many gram-positive and gram-negative organisms.
    [Show full text]
  • Subpart J—Certain Other Dosage Forms [Reserved] PART
    Pt. 448 21 CFR Ch. I (4±1±96 Edition) (ii) Samples required: Subpart HÐRectal Dosage Forms (a) The oxytetracycline hydro- [Reserved] chloride used in making the batch: 10 packages, each containing approxi- mately 300 milligrams. Subpart IÐ[Reserved] (b) The polymyxin B sulfate used in making the batch: 10 packages, each Subpart JÐCertain Other Dosage containing approximately 300 milli- Forms [Reserved] grams. (c) The batch: A minimum of 30 tab- PART 448ÐPEPTIDE ANTIBIOTIC lets. DRUGS (b) Tests and methods of assayÐ(1) Po- tencyÐ(i) Oxytetracycline content. Pro- Subpart AÐBulk Drugs ceed as directed in § 436.106 of this chap- ter, preparing the sample for assay as Sec. 448.10 Bacitracin. follows: Place a representative number 448.10a Sterile bacitracin. of tablets into a high-speed glass blend- 448.13 Bacitracin zinc. er jar containing sufficient 0.1N hydro- 448.13a Sterile bacitracin zinc. chloric acid to obtain a stock solution 448.15a Sterile capreomycin sulfate. of convenient concentration containing 448.20a Sterile colistimethate sodium. not less than 150 micrograms of oxytet- 448.21 Colistin sulfate. racycline per milliliter (estimated). 448.23 Cyclosporine. Blend for 3 to 5 minutes. Remove an al- 448.25 Gramicidin. iquot of the stock solution and further 448.30 Polymyxin B sulfate. dilute with sterile distilled water to 448.30a Sterile polymyxin B sulfate. the reference concentration of 0.24 448.75 Tyrothricin. microgram of oxytetracycline per mil- liliter (estimated). Subpart BÐOral Dosage Forms (ii) Polymyxin B content. Proceed as 448.121 Colistin sulfate for oral suspension. directed in § 436.105 of this chapter, pre- 448.123 Cyclosporine oral dosage forms.
    [Show full text]
  • (ESVAC) Web-Based Sales and Animal Population
    16 July 2019 EMA/210691/2015-Rev.2 Veterinary Medicines Division European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) Sales Data and Animal Population Data Collection Protocol (version 3) Superseded by a new version Superseded Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. Table of content 1. Introduction ....................................................................................................................... 3 1.1. Terms of reference ........................................................................................................... 3 1.2. Approach ........................................................................................................................ 3 1.3. Target groups of the protocol and templates ......................................................................... 4 1.4. Organization of the ESVAC project ...................................................................................... 4 1.5. Web based delivery of data ................................................................................................ 5 2. ESVAC sales data ............................................................................................................... 5 2.1.
    [Show full text]
  • New Antibiotics for the Treatment of Acute Bacterial Skin and Soft Tissue Infections in Pediatrics
    pharmaceuticals Review New Antibiotics for the Treatment of Acute Bacterial Skin and Soft Tissue Infections in Pediatrics Nicola Principi 1, Alberto Argentiero 2, Cosimo Neglia 2, Andrea Gramegna 3,4 and Susanna Esposito 2,* 1 Università degli Studi di Milano, 20122 Milan, Italy; [email protected] 2 Pediatric Clinic, Pietro Barilla Children’s Hospital, Department of Medicine and Surgery, University of Parma, 43121 Parma, Italy; [email protected] (A.A.); [email protected] (C.N.) 3 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, 20122 Milan, Italy; [email protected] 4 Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy * Correspondence: [email protected]; Tel.: +39-052-190-3524 Received: 29 September 2020; Accepted: 19 October 2020; Published: 23 October 2020 Abstract: Acute bacterial skin and soft tissue infections (aSSTIs) are a large group of diseases that can involve exclusively the skin or also the underlying subcutaneous tissues, fascia, or muscles. Despite differences in the localization and severity, all these diseases are due mainly to Gram-positive bacteria, especially Staphylococcus aureus and Streptococcus pyogenes. aSSTI incidence increased considerably in the early years of this century due to the emergence and diffusion of community-acquired methicillin-resistant S. aureus (CA-MRSA). Despite the availability of antibiotics effective against CA-MRSA, problems of resistance to these drugs and risks of significant adverse events have emerged. In this paper, the present knowledge on the potential role new antibiotics for the treatment of pediatric aSSTIs is discussed. The most recent molecules that have been licensed for the treatment of aSSTIs include ozenoxacin (OZ), ceftaroline fosamil (CF), dalbavancin (DA), oritavancin (OR), tedizolid (TD), delafloxacin (DL), and omadacycline (OM).
    [Show full text]
  • WHO Model List (Revised April 2003) Explanatory Notes
    13th edition (April 2003) Essential Medicines WHO Model List (revised April 2003) Explanatory Notes The core list presents a list of minimum medicine needs for a basic health care system, listing the most efficacious, safe and cost-effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost-effective treatment. The complementary list presents essential medicines for priority diseases, for which specialized diagnostic or monitoring facilities, and/or specialist medical care, and/or specialist training are needed. In case of doubt medicines may also be listed as complementary on the basis of consistent higher costs or less attractive cost-effectiveness in a variety of settings. When the strength of a drug is specified in terms of a selected salt or ester, this is mentioned in brackets; when it refers to the active moiety, the name of the salt or ester in brackets is preceded by the word "as". The square box symbol (? ) is primarily intended to indicate similar clinical performance within a pharmacological class. The listed medicine should be the example of the class for which there is the best evidence for effectiveness and safety. In some cases, this may be the first medicine that is licensed for marketing; in other instances, subsequently licensed compounds may be safer or more effective. Where there is no difference in terms of efficacy and safety data, the listed medicine should be the one that is generally available at the lowest price, based on international drug price information sources.
    [Show full text]
  • Third ESVAC Report
    Sales of veterinary antimicrobial agents in 25 EU/EEA countries in 2011 Third ESVAC report An agency of the European Union The mission of the European Medicines Agency is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health. Legal role Guiding principles The European Medicines Agency is the European Union • We are strongly committed to public and animal (EU) body responsible for coordinating the existing health. scientific resources put at its disposal by Member States • We make independent recommendations based on for the evaluation, supervision and pharmacovigilance scientific evidence, using state-of-the-art knowledge of medicinal products. and expertise in our field. • We support research and innovation to stimulate the The Agency provides the Member States and the development of better medicines. institutions of the EU the best-possible scientific advice on any question relating to the evaluation of the quality, • We value the contribution of our partners and stake- safety and efficacy of medicinal products for human or holders to our work. veterinary use referred to it in accordance with the • We assure continual improvement of our processes provisions of EU legislation relating to medicinal prod- and procedures, in accordance with recognised quality ucts. standards. • We adhere to high standards of professional and Principal activities personal integrity. Working with the Member States and the European • We communicate in an open, transparent manner Commission as partners in a European medicines with all of our partners, stakeholders and colleagues. network, the European Medicines Agency: • We promote the well-being, motivation and ongoing professional development of every member of the • provides independent, science-based recommenda- Agency.
    [Show full text]